Durvalumab (Imfinzi)
Durvalumab (Imfinzi) is a programmed death-ligand 1 (PD-L1)–blocking antibody and immune checkpoint inhibitor drug.
Durvalumab has multiple indications. It is approved in combination with other drugs for the treatment of:
- Metastatic non-small cell lung cancer
- Extensive-stage small cell lung cancer
- Locally advanced or metastatic biliary tract cancer
- Hepatocellular carcinoma and endometrial cancer that is mismatch repair deficient
Provider Resource
